As of close of business last night, Atara Biotherapeutics Inc’s stock clocked out at $0.75, down -0.89% from its previous closing price of $0.76. In other words, the price has decreased by -$0.0067 from its previous closing price. On the day, 681324 shares were traded.
Ratios:
To gain a deeper understanding of ATRA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.65 and its Current Ratio is at 0.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on November 09, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $31 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Touchon Pascal sold 24,844 shares for $0.72 per share. The transaction valued at 17,888 led to the insider holds 1,910,652 shares of the business.
Nguyen AnhCo sold 10,746 shares of ATRA for $7,737 on Mar 04 ’24. The EVP, Chief Sci. & Tech Officer now owns 941,397 shares after completing the transaction at $0.72 per share. On Mar 04 ’24, another insider, Murugan Amar, who serves as the EVP, Chief Legal Officer of the company, sold 10,044 shares for $0.72 each. As a result, the insider received 7,232 and left with 727,521 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATRA now has a Market Capitalization of 90.71M and an Enterprise Value of 96.86M. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.44. Its current Enterprise Value per Revenue stands at 11.30 whereas that against EBITDA is -0.36.
Stock Price History:
Over the past 52 weeks, ATRA has reached a high of $3.08, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is 0.7587, while the 200-Day Moving Average is calculated to be 1.1479.
Shares Statistics:
It appears that ATRA traded 3.02M shares on average per day over the past three months and 1.26M shares per day over the past ten days. A total of 119.36M shares are outstanding, with a floating share count of 110.12M. Insiders hold about 7.74% of the company’s shares, while institutions hold 60.76% stake in the company. Shares short for ATRA as of Mar 15, 2024 were 11.03M with a Short Ratio of 3.65, compared to 10.87M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.82% and a Short% of Float of 11.09%.
Earnings Estimates
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.23 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.33, while EPS last year was -$0.72. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.03 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$0.4 and -$1 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.55, with 4 analysts recommending between -$0.05 and -$1.15.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $27.92M. It ranges from a high estimate of $41.27M to a low estimate of $15.5M. As of the current estimate, Atara Biotherapeutics Inc’s year-ago sales were $1.23M, an estimated increase of 2,177.30% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $31.3M, an increase of 730.20% less than the figure of $2,177.30% in the same quarter last year. There is a high estimate of $40M for the next quarter, whereas the lowest estimate is $16M.
A total of 4 analysts have provided revenue estimates for ATRA’s current fiscal year. The highest revenue estimate was $179.88M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $100.47M. In the same quarter a year ago, actual revenue was $8.57M, up 1,071.90% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $83.06M in the next fiscal year. The high estimate is $128M and the low estimate is $16M. The average revenue growth estimate for next year is down -17.30% from the average revenue estimate for this year.
